Sana Biotechnology CEO Steve Harr shares the company’s progress in overcoming allogeneic rejection and an update on Sana’s pipeline heading into 2024. More from Flagship @ JPM2024 here.
Related Companies
- Sana Biotechnology Founded: 2018
More from:
Human Health
